









































Lymphatic tumour spread and its implications for treatment
and survival have been studied for centuries. Different theo-
ries regarding the dissemination of solid tumours have
been introduced, based on experimental data and observa-
tions during follow-up of cancer patients. These resulted in
discussion about the place of regional lymph node dissec-
tion in the treatment of diseases that were thought either to
be systemic from the beginning or to spread initially to
lymph nodes. Elective regional lymph node dissections
became controversial because of overtreatment of the
many patients without lymph node metastases. These
patients suffer from associated morbidity without survival
benefit. With the introduction of the sentinel node concept,
a minimally invasive procedure became available for detec-
tion of occult lymph node metastases. This report
describes the history and the validation of the technique,
with particular reference to breast cancer.
Dissemination theories
Bartholin was the first to notice the existence of a ‘lym-
phatic’ in 1653. Numerous subsequent investigations elu-
cidated the intricate lymphatic system. Virchow, in the
nineteenth century, formulated the theory that lymph
nodes filter particulate matter from lymph. This important
assumption led to the awareness that cancer could be
cured at an early stage with adequate surgery, in contra-
diction to the Greek philosophy implying that cancer is the
local manifestation of a systemic disease. The next logical
step in the evolution of Virchow’s theory was the introduc-
tion of the radical mastectomy by Halsted at the end of the
nineteenth century [1].
To determine the barrier function of lymph nodes, several
investigators injected inanimate particles or tumour cells
into certain afferent lymphatics in animal models. Study-
ing mesenteries of dogs and rabbits, Gilchrist saw no
passage of carbon suspensions through any node after
injections with varying pressures [2]. Zeidman and Buss
injected stained V2 carcinoma cells into the afferent lym-
phatics of popliteal nodes in rabbits [3]. They found that
tumour cell emboli are immediately trapped in the sub-
capsular sinus and do not spread to the next node for at
least 3 weeks.
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The Halstedian model with en bloc dissection as the
guiding principle of cancer surgery lost ground when the
systemic hypothesis was reintroduced in the 1960s.
Nodal involvement was suggested not to be an orderly
contiguous extension, but rather a marker of distant
disease [4]. Fisher and Fisher found that less than 40% of
51Cr-labelled V2 carcinoma cells were retained in a rab-
bit’s popliteal node [5]. This finding was explained by the
presence of lymphaticovenous pathways in lymph nodes,
although the existence of free communication between the
venous and lymphatic system is controversial. The ineffec-
tiveness of the lymph node barrier is not in line with the
better prognosis of cancer patients without nodal involve-
ment. Alternative theories were considered. Tumour cells
that traverse lymph nodes could be destroyed more
readily or are less apt to develop distant metastases.
Tumour cells that remain in lymph nodes could be those
forming secondary tumours [5].
The spectrum hypothesis may be the most consistent with
clinical observations. Hellman noted that breast cancer is
best thought of as a spectrum of disease with increasing
inclination towards metastasising as a function of tumour
growth and progression [4]. A lymph node metastasis may
either be the only site of dissemination, especially in small
tumours, or can be a marker of distant disease. The obser-
vation that many cancer patients are cured after adequate
locoregional treatment illustrates why the spectrum theory
is attractive. The introduction of the sentinel node concept
was a logical attempt to clarify the controversy caused by
the described hypotheses.
First descriptions of a sentinel node
A normal-appearing node at the junction of the anterior
and posterior facial vein was sent for frozen section inves-
tigation during a total parotidectomy in 1951. In the
description of Gould, the pathology report was ‘lymph
node with metastatic tumour’ [6]. Intraoperative examina-
tion of this lymph node in its typical anatomical location
guided the decision to perform a radical neck dissection
during the following parotidectomies.
Two decades later, Cabañas observed the existence of a
sentinel node in the lymphatic drainage of the penis [7].
Lymphangiographic studies elucidated the precise loca-
tion of such sentinel nodes. Direct drainage from the penis
to the lymph nodes associated with the superficial epigas-
tric vein was observed. After making an incision parallel to
the inguinal ligament, the sentinel lymph node was identi-
fied by inserting the finger under the upper flap toward the
pubic tubercle.
Studying lymphatic drainage of testicular cancer also
revealed the existence of a sentinel node. Chiappa et al
postulated primary testicular lymph centres using lym-
phangiographic studies [8]. More knowledge about the
primary metastatic sites of testicular cancer was later
obtained through surgical and histopathological explo-
ration of the retroperitoneum. Weissbach and Boedefeld
examined the feasibility of a limited retroperitoneal lymph
node dissection, based on their observations of areas in
which solitary metastases occur. Lymph nodes in these
areas were called sentinels [9]. Weissbach and Boedefeld
stated that ‘a more limited approach strictly for the
purpose of pathological staging, which aims at the preven-
tion of long-term damage without compromising diagnos-
tic accuracy, must be based on the knowledge of the
pathways of lymphatic dissemination and, particularly, on
the first sites of nodal involvement’.
Kett et al administered contrast medium in breast lymphat-
ics that were visualised with the aid of areolar blue dye
injection [10]. They observed flow to an isolated lymph
node, called the ‘Sorgius’ node, and subsequent drainage
through many lymphatic vessels and lymph nodes to the
collecting system around the axillary vein. Using breast
lymphoscintigraphy in 1980, Christensen et al observed
‘primary draining nodes’ [11]. Haagensen studied the
route of metastases through the axillary lymph node filter
and stated that the nodes of the central group are not only
most often involved, but also most often exclusively
involved [12]. An interesting finding is that he used the
term sentinel node for specific lymph nodes of the inferior
deep cervical group because of their close relationship to
the jugular–subclavian venous confluence.
The concept of lymphatic mapping with
sentinel node biopsy
It is remarkable in light of the previous descriptions that the
concept of lymphatic mapping was not introduced until the
end of the twentieth century. Morton et al have used cuta-
neous lymphoscintigraphy with colloidal gold since 1977
to identify the lymphatic drainage pattern of melanomas
located at ambiguous sites [13]. In addition to this preoper-
ative procedure, they also developed a technique for intra-
operative mapping to selectively remove lymph nodes on
the direct drainage pathway from the primary melanoma.
This sentinel node was considered to be the first site of
metastatic disease. The work of the group at the John
Wayne Cancer Institute initiated one of the most interest-
ing recent developments in surgical oncology.
The concept of sentinel node biopsy is based on two basic
principles: the existence of an orderly and predictable
pattern of lymphatic drainage to a regional lymph node
basin, and the functioning of a first lymph node as an effec-
tive filter for tumour cells. With the widespread use of sen-
tinel node biopsy, sufficient data was provided to prove
that sequential lymphatic dissemination and entrapment of
tumour cells in first draining lymph nodes occur [14,15].
The sentinel node concept is actually based on the Halsted







































treatment because of the step-wise spread. The spectrum
and systemic hypotheses, however, suggest that lymph
node involvement can be an indicator of distant disease
and therefore sentinel node biopsy is also a staging tool to
select patients for adjuvant systemic treatment.
Evolution of the technique of lymphatic
mapping
The static approaches for sentinel node biopsy applied
from halfway through the twentieth century did not produce
any enthusiasm for the concept. The reason for this might
be that these techniques, only based on the typical
anatomical patterns, were not reproducible and did not
take into account the interindividual variability of lymphatic
drainage. The introduction of the blue dye mapping by
Morton and coworkers was the key point in the general
acceptance of sentinel node biopsy. After a feasibility study
in a feline model, they injected patent blue or isosulfan blue
intradermally at the primary tumour site in melanoma
patients. An incision was subsequently made over the site
of expected lymphatic drainage, and the lymphatic channel
was visually identified. This channel was followed to the
first draining lymph node by meticulous dissection. This
technique of intraoperative lymphatic mapping was pre-
sented at the World Health Organisation’s Second Interna-
tional Conference on Melanoma in 1989 [16]. Morton et
al’s original report followed 3 years later [13].
Visualisation of lymphatic drainage is not new. Haagensen
et al describe the old anatomical studies using injections
of various tracer fluids in The Lymphatics in Cancer [17].
Sappey tried to clarify the intricate lymphatic system of the
breast using mercury injections at the end of the eigh-
teenth century. Surgeons and nuclear medicine physicians
later visualised the lymphatic system with vital dyes and
radioactive isotopes. Finally, it was a multidisciplinary team
at the John Wayne Cancer Institute in Santa Monica which
combined the visualisation of lymphatic drainage with the
sentinel node concept in melanoma patients.
The development of sentinel node biopsy in breast cancer
also started at the John Wayne Cancer Institute in 1991.
The first article of blue dye mapping in breast cancer by
Guiliano et al was published in 1994 [18]. Injection of
radiolabelled colloids with intraoperative detection of the
sentinel node using a gamma-ray detection probe was
introduced a little later [19]. Preoperative lymphoscintigra-
phy was added for better specification of the location and
number of sentinel nodes. Different methodologies based
on these two lymphatic mapping techniques are nowa-
days applied all over the world.
Validation of the sentinel node concept
In initial sentinel node procedures in 34 breast cancer
patients, Giuliano reported that tumour was found in 39
of 63 sentinel nodes (62%) compared with 93 of 688
non-sentinel nodes (14%). He stated that ‘this suggests
that a primary breast carcinoma spreads to the axilla
along a specific pathway of lymph nodes that cannot be
identified by random axillary sampling’ [20]. But the
main question is whether absence of tumour cells in the
sentinel node is indicative of the absence of tumour
cells in the other lymph nodes of the regional basin. An
important parameter in studies concerning this question
is the false negative rate. The false negative rate is the
number of false negative procedures divided by the sum
of the true positive and false negative procedures
(1 – sensitivity), although some investigators calculate it
in their own way.
Morton  et al found, in the first 194 lymphadenectomy
specimens that had an identifiable sentinel node, that non-
sentinel nodes were the sole site of melanoma metastasis
in only two patients [13]. The sentinel node was involved
with tumour in 38 patients, resulting in a false negative
rate of 5% (2/40). This result showed a high degree of
accuracy in identifying early-stage melanoma patients with
clinically occult lymph node metastases and suggests that
the concept is valid. With extensive pathological examina-
tion of sentinel nodes and non-sentinel nodes in breast
cancer, Turner et al described that, if the sentinel node is
tumour free, the probability of involvement of a non-sen-
tinel node is 1 in 1087 [21]. Numerous studies in
melanoma and breast cancer patients have confirmed that
the sentinel node is the first node reached by metastasis-
ing cells as they enter the regional lymphatic basin in the
vast majority of patients. A review of sentinel node biopsy
in breast cancer reported an accuracy of more than 95%
in all studies [22]. A wide range of false negative rates
among different centres does, however, exist. Unaccept-
able failure rates can occur because of technique, physi-
cian and patient related factors. The first observational
study of sentinel node biopsy not followed by routine axil-
lary lymph node dissection in 133 breast cancer patients
showed no axillary recurrences after a median follow-up of
39 months [23].
Conclusion
The development of the sentinel node concept is a
recent milestone in the understanding of dissemination
of solid malignancies. The concept is based on Halsted’s
theory and the experimental work of Gilchrist, Zeidman
and others, which supported the hypothesis of sequen-
tial dissemination through the lymphatic system. After
incidental reports of non-guided sentinel node proce-
dures, it was the introduction of the technique of intraop-
erative lymphatic mapping in 1989 that initiated the
widespread use and general acceptance of this
approach. Now that the technique has been validated,
many breast cancer patients are spared a regional lymph
node dissection without compromising local control and
the accuracy of staging.
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